论文部分内容阅读
目的观察拉米夫定结合胸腺肽抗病毒治疗对合并肝炎肝癌术后的复发和生存时间影响。方法2000年1月-2003年12月,70例合并肝炎肝癌随机分为两组。对照组为手术切除组(n=35),治疗组(n=35)为手术切除加术后拉米夫定结合胸腺肽抗病毒治疗,观察两组HBV-DNA清除率、HBeAg转阴率、复发时间和生存时间。结果治疗组和对照组比较,1、2年HBV-DNA清除率分别为98%比0%和100%比4%(P=0.0000,0.0000),HBeAg转阴率分别为60.0%比6.0%和73.5%比7.5%(P=0.002),中位复发时间分别为10.0个月比6.5个月(P=0.0032),中位生存时间分别为12.5个月比6.0个月(P=0.0021)。结论拉米夫定结合胸腺肽抗病毒治疗有助于合并活动性肝炎肝癌术后清除病毒复制,延迟复发,提高生存时间。
Objective To observe the effect of lamivudine combined with thymosin antiviral therapy on postoperative recurrence and survival time of hepatocellular carcinoma with hepatitis. Methods From January 2000 to December 2003, 70 patients with hepatocellular carcinoma (HCC) were randomly divided into two groups. In the control group, the patients in the surgical resection group (n = 35) and the treatment group (n = 35) were treated with lamivudine plus thymosin combined with antiviral therapy. The HBV DNA clearance rate, HBeAg negative rate, relapse Time and survival time. Results Compared with the control group, the clearance rates of HBV DNA for 1 and 2 years were 98% vs 0% and 100% vs 4%, respectively (P = 0.0000, 0.0000), and the HBeAg negative rates were 60.0% and 6.0% 73.5% versus 7.5% (P = 0.002). The median time to recurrence was 10.0 months vs 6.5 months (P = 0.0032). The median survival time was 12.5 months vs 6.0 months (P = 0.0021). Conclusions Lamivudine combined with thymosin antiviral therapy is helpful to remove viral replication, delay relapse and improve survival time after active hepatitis treatment.